Adults and adolescents 12 years of age and older living with asthma may qualify for a clinical research study evaluating an investigational medication designed to help reduce asthma attacks and improve long-term disease control.
Adults and adolescents 12 years of age and older living with asthma may qualify for a clinical research study evaluating an investigational medication designed to help reduce asthma attacks and improve long-term disease control.
This research study is evaluating depemokimab, an investigational medication, to determine whether earlier treatment with this therapy may help reduce asthma exacerbations, improve symptom control, and slow lung function decline. Depemokimab is a type of biologic therapy designed to target inflammation associated with Type 2 asthma. Researchers will compare depemokimab to placebo to assess its effectiveness, safety, and tolerability.
You may be able to join if you:
Adults and adolescents 12 years of age and older living with asthma may qualify for a clinical research study evaluating
Adults 40–75 who have COPD and experienced a flare-up in the past year may qualify for a study evaluating an
Adults 18 and older living with post-traumatic stress disorder (PTSD) may qualify for a clinical research study evaluating an investigational
Individuals with bronchiectasis who experience frequent flare-ups or ongoing respiratory symptoms may qualify for a research study evaluating a home
Researchers are studying an investigational medication to see how effective it may be in reducing risk of heart failure for
Suburban Research Associates is conducting a clinical research study for adults with Idiopathic Hypersomnia for an upcoming study on daytime